Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly
failed in clinical trials. Together with numerous reports that amyloid is present in brains from …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Alzheimer's disease (AD) is the most common neurodegenerative disorders presenting with
the pathological hallmarks of amyloid plaques and tau tangles. Over the past few years …

Accumulation of phosphorylated tau is a key pathological feature of Alzheimer's disease.
Phosphorylated tau accumulation causes synaptic impairment, neuronal dysfunction and …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Our study utilizes a longitudinal isotopic metabolic labeling approach in vivo in combination
with organelle fraction proteomics to address the role of parkin in mitochondrial protein …

Alzheimer's disease (AD) is a major cause of age-related dementia and is characterized by
progressive brain damage that gradually destroys memory and the ability to learn, which …

Introduction The entorhinal cortex is among the earliest areas involved in Alzheimer's
disease. Volume reduction and neural loss in this area have been widely reported. Human …

The hippocampus and entorhinal cortex (EC), the earliest affected areas, are considered
relative to early memory loss in Alzheimer's disease (AD). The hippocampus is composed of …

Objective To identify the molecular signaling pathways underlying sudden unexpected
death in epilepsy (SUDEP) and high-risk SUDEP compared to control patients with epilepsy …